Independent directory Public ClinicalTrials.gov records United States
Condition Directory

Alzheimer's Disease clinical trials

Directory of U.S. ClinicalTrials.gov public records for Alzheimer's Disease. Browse Alzheimer's Disease recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 14, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
707
Shown on this page
12
Current sort
Recently updated
Condition scope
Alzheimer's Disease
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Alzheimer's Disease studies are organized in the registry

The registry typically spells this condition “Alzheimer disease” (without the apostrophe-s), and both spellings appear across listings. Early-stage research uses its own vocabulary — prevention and early-intervention studies are often filed under “mild cognitive impairment,” “prodromal,” or “preclinical” rather than the disease name, and some enroll cognitively healthy volunteers at elevated risk. This directory also has a dedicated mild cognitive impairment page.

Terms that often appear in related listings

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Alzheimer's Disease. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 169–180 of 707 matching trials for Alzheimer's Disease.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting No phase listed Observational Accepts healthy volunteers

Genetic Studies of Early-onset Dementia

NCT04906863
Conditions
Dementia, Early Onset, Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI), Memory Loss
Interventions
Blood draw, Neurocognitive testing, Medical questionnaire
Genetic · Other
Lead sponsor
Columbia University
Other
Eligibility
35 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Alzheimer Disease
Interventions
Choline
Drug
Lead sponsor
Paul E Schulz
Other
Eligibility
55 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cognitive Dysfunction
Interventions
adMSC
Biological
Lead sponsor
Paul E Schulz
Other
Eligibility
60 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Long-Term Care Planning
Interventions
PlanYourLifespan.org
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
55 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Alzheimer Disease
Interventions
Memantine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 83 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Diego, California
Conditions
Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection, MK6240
Other · Radiation
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 90 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
22
States / cities
Atlantis, Florida • Aventura, Florida • Clermont, Florida + 19 more
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Neuroinflammation Imaging in AD

NCT04274998
Conditions
Alzheimer Disease, Healthy Volunteer
Interventions
[18F]NOS, [11C]PBR28
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Recruiting Phase 2 Interventional Accepts healthy volunteers

Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol

NCT07012993
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia, Healthy Volunteers
Interventions
18F-Florbetapir or 18F-Flutemetamol
Drug
Lead sponsor
Akiva Mintz
Other
Eligibility
18 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Englewood, New Jersey
Conditions
Alzheimer Disease
Interventions
MAR
Drug
Lead sponsor
Noah Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Scottsdale, Arizona • Huntington Beach, California • DeLand, Florida + 11 more
Completed Phase 2 Interventional Accepts healthy volunteers

Treating Hyperexcitability in AD With Levetiracetam

NCT03875638
Conditions
Alzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type, Mild Cognitive Impairment
Interventions
Levetiracetam, Placebo oral capsule
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting No phase listed Observational Accepts healthy volunteers

Selective PET Imaging of Astrocytes and Microglia in Alzheimer's Disease

NCT05582200
Conditions
Alzheimer Disease, Healthy
Interventions
Positron Emission Tomography (PET) using 11C-ER176 for TSPO and 18F-SMBT1 for MAO-B
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Alzheimer Disease, Cognitive Dysfunction, Dementia
Interventions
JNJ-63733657, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
55 Years to 80 Years
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 47 more

About this Alzheimer's Disease clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Alzheimer's Disease as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Alzheimer's Disease.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Alzheimer's Disease.